Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. - Wikidata - wikimedia - TriplyDB

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.

http://www.wikidata.org/entity/Q43941683

about

Oncolytic viruses as therapeutic cancer vaccines New viruses for cancer therapy: meeting clinical needs Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2 Intelligent design: combination therapy with oncolytic viruses The status of gene therapy for brain tumors Sui generis: gene therapy and delivery systems for the treatment of glioblastoma Genetic, immunological, and pharmacological strategies to generate improved oncolytic viruses Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy Oncolytic virotherapy of canine and feline cancer Oncolytic viruses as anticancer vaccines Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Tumor-specific delivery of biologics by a novel T-cell line HOZOT.Human gene therapy and imaging in neurological diseases.Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.Inhibitors of C5 complement enhance vaccinia virus oncolysis.Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy Conditionally replicating herpes vectors for cancer therapy.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice Replicative adenoviruses for cancer therapy.VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.Oncolytic viruses as novel anticancer agents: turning one scourge against another.Molecular advances to treat cancer of the brain.Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.Combination of viral oncolysis and tumor-specific immunity to control established tumors Directing systemic oncolytic viral delivery to tumors via carrier cells Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses Oncolytic adenoviruses for treatment of brain tumours.The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider.

P2860

Q21245758-99CE8B31-A229-4639-A81D-5372E9518902 Q24567699-DBA38F26-6DD5-4FE3-B3FE-D129CFFA74F4 Q24596171-4BF7DE96-C16B-45AD-BD48-2AB87ABE8139 Q24612603-A8B8AB54-A377-409A-A756-C4384D59AA3F Q24628227-79128943-77BA-44BF-B939-7A19D819AA63 Q24651009-0226B4FC-6B6D-4660-989A-867FCCD3985E Q26850467-BFC65733-B069-4895-A533-6FEF76BF339B Q26859879-73CEDE25-EAA9-4719-A28C-E9EBFAC0ADA5 Q26863779-E53935F8-7644-4971-8550-0962E8930272 Q26998111-87BBD13B-226C-4ADA-8A0F-AED6B764EE08 Q27008306-BDF0DB31-1211-48CB-8411-D9F1CB13A8D2 Q27025600-60C62011-DAF0-441D-B3D5-D4E0A890F30D Q27690634-70A32D7C-A4B7-46E3-8EBB-0318DB752256 Q30830225-102AF876-86E8-43F5-803E-E55576AA9A1B Q31023442-61651D5D-AEB1-4A2C-93E3-EB12D526F47B Q33580223-30FC3E35-B649-4FBB-84DC-A85FB827B679 Q33641230-F973EF8F-0CDD-4D24-B40A-67D3927E3FBF Q33675567-5C1EEAC8-08E7-4B78-B7E9-81EEFFF03584 Q33713908-3FF11239-4DE1-4919-A9ED-4A0C0883CEEE Q33768177-1AED9D40-0136-43EF-90A6-EB55F63A4CC7 Q33773376-AD29E451-287B-4464-AD9E-9BF3C9E1FC31 Q33804845-7E7DF7AC-0F7A-4A16-9EAC-519EF2427889 Q33813146-05F6AEFF-2CCE-468D-8282-24E1E56EF669 Q33822168-A2A03A38-59B1-4D23-9ED8-CA1CC02B9E34 Q33882697-0B73A779-A561-433B-BC9A-9232B547E7DE Q33906116-B14AED6A-B518-487A-8F85-B521C832344C Q33927165-C764C0BB-E6BB-47D2-BB53-94E5C11A92CB Q33963944-6F169358-DE15-4ED1-83CD-158DCB31A1C1 Q33976318-4569B16A-6790-42A6-97BC-5ED2E3F62E91 Q34074708-677F2966-963A-4BEE-82F1-881EF2B3B1E2 Q34074888-152C501F-DC40-4B4F-AFF4-F319EF9999AA Q34297058-C2810047-D81E-4013-B336-8A95FCB7E81D Q34316241-BC289FF3-5961-49EB-AA55-764DF2F0BB28 Q34621654-A7B06649-4366-4D08-8FBF-3941649ED125 Q34790267-41D585EA-4907-4ABC-BF8B-45565554ACCD Q34793516-0DAE1488-7F8A-49AB-A244-8FF1F2D5FBA0 Q35029126-9445D2EE-78F0-4C5A-A003-4E07953B7134 Q35036505-01D920C2-2B45-4C3B-8190-E8445FC40399 Q35040863-39300EC2-B3A1-4DF4-8FB1-DF47F4E6D632 Q35043121-FB29F58A-D326-4116-A68B-2761B3981DE8

P2860

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.

http://www.wikidata.org/entity/Q43941683

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

Oncolytic virus therapy of mul ...... elicited antiviral responses.

@en

Oncolytic virus therapy of mul ...... elicited antiviral responses.

@nl

type

label

Oncolytic virus therapy of mul ...... elicited antiviral responses.

@en

Oncolytic virus therapy of mul ...... elicited antiviral responses.

@nl

prefLabel

Oncolytic virus therapy of mul ...... elicited antiviral responses.

@en

Oncolytic virus therapy of mul ...... elicited antiviral responses.

@nl

P1433

Q43941683-A03CD860-A194-4A1F-B8DE-C9F5AB07CE0D

P1476

Q43941683-57214748-1D0C-4F8D-9659-0EFA8D76E0FD

P2093

Q43941683-1752E212-7766-4F3D-8E80-1448D4ED7112

Q43941683-2B8BC0E5-35B6-4B6A-919C-DFBC4ECB0262

Q43941683-31053460-50C7-4196-8C83-BCBA2EA3A7C1

Q43941683-3BF5C611-29E4-4554-93A9-3EB2F7995046

Q43941683-50B8BE9E-68E3-4FEE-AB72-FA82F574CE55

Q43941683-68AEE081-41F8-4690-B1CD-9C3A19C8AC99

Q43941683-9BF77C8D-445E-4B37-9AA2-F77AA44DE2DF

Q43941683-B191B646-41B3-47DB-B704-E39B3550F434

Q43941683-B99F4DA7-0A8B-4577-B6BE-6972C345D9EF

Q43941683-BB3AFF8F-3CEA-44E3-93EF-6983A339D01F

P2888

Q43941683-1DDD9020-27CE-48B0-8BC1-5D59D2356943

P304

Q43941683-4A9ADDF8-A2C8-477D-A48F-6948F96A8C90

P31

Q43941683-4D0087A5-7585-4D72-88D1-2EA673DA9914

P356

Q43941683-4E6F4280-79DB-4DB1-AE73-3DB2D9F02DD3

P407

Q43941683-01D2FBCA-24C3-49D6-B37F-644395D87FE9

P433

Q43941683-8979744E-9D26-4FA8-B66A-1FFA134F228F

P478

Q43941683-410C7CFE-C57E-4428-B7A5-D54E58E88E26

P577

Q43941683-FF8D05A3-965C-4709-BD4D-16CA5C886177

P698

Q43941683-1A989C60-39BC-4F4D-AC0F-C40396A75C72

P921

Q43941683-7D8ECB21-0933-4629-AB15-6F90FFFED8A8

P356

P1433

Nature Medicine

P1476

Oncolytic virus therapy of mul ...... elicited antiviral responses.

@en

P2093

Bartus RT

http://www.w3.org/2001/XMLSchema#string

Chiocca EA

http://www.w3.org/2001/XMLSchema#string

Deisboeck TS

http://www.w3.org/2001/XMLSchema#string

Finkelstein D

http://www.w3.org/2001/XMLSchema#string

Harsh GR 4th

http://www.w3.org/2001/XMLSchema#string

Hochberg FH

http://www.w3.org/2001/XMLSchema#string

Ichikawa T

http://www.w3.org/2001/XMLSchema#string

Ikeda K

http://www.w3.org/2001/XMLSchema#string

Louis DN

http://www.w3.org/2001/XMLSchema#string

Silver JS

http://www.w3.org/2001/XMLSchema#string

P2888

P304

881-887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/11320

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

1999-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10426310

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus